COVID-19 : EFFECT ON LUNG CANCER PROGRESS

Main Article Content

BISWARANJAN RAY
S. N. DASH
SWASTIK PUROHIT
SUMIT PRADHAN

Abstract

The advent of corona virus disease 2019 (COVID-19) has caused confusion, changed people's living conditions, including commuting restrictions, fear of disease transmission, The corona virus is  "Aladdin's meracle lamp" for lungs cancer, this is a huge curse for lung cancer patients. As the Root of entry of Virus is Respiratory tract,Complicaion arises in lungs.

The risk of chemotherapy-related infections increases for such patients.  "Targeted therapy is generally safe while the potential interaction between immunotherapy and COVID-19 remains unknown at present”. The Present article focus on Different Immunological fact related to COVID-19 and Physiological degradation of Lungs by Corona Virus and Effect on Lung cancer.

Keywords:
Corona virus, chemotherapy, malignancy, infection, physiology, pathogenesis

Article Details

How to Cite
RAY, B., DASH, S. N., PUROHIT, S., & PRADHAN, S. (2021). COVID-19 : EFFECT ON LUNG CANCER PROGRESS. Asian Journal of Advances in Medical Science, 3(4), 159-168. Retrieved from http://mbimph.com/index.php/AJOAIMS/article/view/2495
Section
Review Article

References

Instituto de Salud Carlos III. Ministerio de Sanidad. Estudio ENE-COVID19: Estudio Nacional de Sero-Epidemiología de la Infección por SARS-CoV-2 en España; 2020.

Available:https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_PRIMERA_RONDA_INFORME_PRELIMINAR.pdf (Accessed 13 May, 2020).

Yang X, Yu Y, Xu J, Shu H, Xia Ja, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Resp Med. 2020;8:475–81.

DOI: 10.1016/S2213-2600(20)30079-5

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–20.

DOI: 10.1101/2020.02.06.20020974

Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368:473.

DOI: 10.1126/science.abb8925

Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020;39:405–7.

DOI: 10.1016/j.healun.2020.03.012

Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncology. 2020;21:335–7.

DOI: 10.1016/S1470-2045(20)30096-6

Liao Z, Rivin Del Campo E, Salem A, Pang Q, Liu H, Lopez Guerra JL. Optimizing lung cancer radiation treatment worldwide in COVID-19 outbreak. Lung Cancer. 2020;146:230-235. DOI:10.1016/j.lungcan.2020.05.029

Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, et al. Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors. Nature; 2020.

DOI: 10.1038/s41586-020-2598-9. [Epub ahead of print].

Lee LYW, Cazier JB, Starkey T, Turnbull CD, U.K.C.Team CMP, Kerr R, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395:1919–26.

DOI: 10.1016/S0140-6736(20)31173-9

Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907–18.

DOI: 10.1016/S0140

Dirección General de Salud Pública. Actualización n° 104. Enfermedad por el Coronavirus (COVID-19). 13.05.2020 (datos consolidados a las 21:00 horas del 12.05.2020); 2020.

Available:https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/Actualizacion_104_COVID-19.pdf

(Accessed 13 May, 2020

del Amo J, Polo R, Moreno S, Díaz A, Martínez E, Arribas JR, et al. Incidence and severity of COVID-19 in HIV-Positive persons receiving antiretroviral therapy. Ann Int Med. 2020;M20–3689.

DOI: 10.7326/M20-3689. [Epub ahead of print].

20. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383:120–28.

DOI: 10.1056/NEJMoa2015432

Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020; 135:2033–40.

DOI: 10.1182/blood.2020006000

Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181:1489–501.e15.

DOI: 10.1016/j.cell.2020.05.015

Robilotti EV, Babady NE, Mead PA, Rolling T, Perez-Johnston R, Bernardes M, et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med. 2020;26:1218–223.

DOI: 10.1038/s41591-020-0979-0

Shankar A, Saini D, Bhandari R, et al. Lung cancer management challenges amidst COVID-19 pandemic: hope lives here. Lung Cancer Manag. 2020;9(3):LMT33.

DOI:10.2217/lmt-2020-References0012

Singh AP, Berman AT, Marmarelis ME, et al. Management of lung cancer during the COVID-19 pandemic. JCO Oncol Pract. Published online May 26, 2020. doi:10.1200/OP.20.00

Passaro A, Addeo A, Von Garnier C, et al. ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer. ESMO Open. 2020;5(Suppl 3):e000820.

Guckenberger M, Belka C, Bezjak A, et al. Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. Radiother Oncol. 2020;146:223-229.

Dingemans AC, Soo RA, Jazieh AR, et al. Treatment guidance for patients with lung cancer during the coronavirus 2019 pandemic. J Thorac Oncol. 2020;15(7):1119-1136.

Raskin J, Lebeer M, De Bondt C, Wener R, Janssens A, van Meerbeeck JP. Cancer in the time of COVID-19: expert opinion on how to adapt current practice. Eur Respir J. 2020;55(5):2000959.

Saini KS, de Las Heras B, de Castro J, et al. Effect of the COVID-19 pandemic on cancer treatment and research. Lancet Haematol. 2020;7(6):e432-e435.

Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020;31(7):894-901.

World Health Organisation. [online] COVID-19 and NCSs.

Available:https://www.who.int/docs/default-source/ncds/ncd-covid-19/for-web—rapid-assessment—30-june-2020-(cleared).pdf?sfvrsn=6296324c_20&download=true

Accessed January 2021

Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020; 31:894–901.

DOI: 10.1016/j.annonc.2020.03.296

Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the COVID-19 outbreak. Cancer Discovery. 2020;10:783–91.

DOI: 10.1158/2159-8290.CD-20-0422

Fratino L, Procopio G, Di Maio M, Cinieri S, Leo S, Beretta G. Coronavirus: Older Persons With Cancer in Italy in the COVID-19 Pandemic. Front Oncol. 2020;10:648.

DOI: 10.3389/fonc.2020.00648

Cai H. Sex difference and smoking predisposition in patients with COVID-19. Lancet Resp Med. 2020; 8:e20.

DOI: 10.1016/S2213-2600(20)30117-X

Miyashita H, Mikami T, Chopra N, Yamada T, Chernyavsky S, Rizk D, et al. Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City. Ann Oncol. 2020;31:1088–89.

DOI: 10.1016/j.annonc.2020.04.006

Gemelli Generator, “Gemelli: an app dedicated to cancer patients and staff for monitoring during the pandemic” [Press release], 18 November 2020,

Available:https://gemelligenerator.it/per-te-paziente-news/gemelli-una-appdedicata-a-pazienti-oncologici-e-personale-per-il-monitoraggio-durante-la-pandemia/ Accessed January 2021

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62.

DOI: 10.1016/S0140-6736(20)30566-3

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.

DOI:10.1016/S0140-6736(20)30183-5

Wu C, Chen X, Cai Y, Xia Ja, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Int Med. 2020;180:934–43.

DOI: 10.1001/jamainternmed.2020.0994

Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020;323:2052–9.

DOI: 10.1001/jama.2020.6775

Guan W-J, Liang W-H, Zhao Y, Liang H-R, Chen Z-S, Li Y-M, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Resp J. 2020;55:2000547.

DOI: 10.1183/13993003.00547-2020

Lai, Alvina, “Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study. BMJ Open. 2020;10(11).

Available https://bmjopen.bmj.com/content/10/11/e043828. Accessed January 2021

Available:https://www.pulmonologyadvisor.com/home/topics/lung-cancer/lung-cancer-in-the-time-of-covid-19-challenges-and-solutions/

The TERAVOLT Global Consortium; 2020.

Available:http://teravolt-consortium.org/

Accessed January 2021

Available:https://www.webmd.com/lung/coronavirus-covid-19-affects-body

Luo J, Rizvi H, Preeshagul I, et al. COVID-19 in patients with lung cancer. Annals of Oncology; Published online 16 June 2020.

DOI:https://doi.org/10.1016/j.annonc.2020.06.007

Zahorec R. Ratio of neutrophil to lymphocyte counts–rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy. 2001;102:5–14.

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130:2620–9.

DOI: 10.1172/JCI137244

Teuwen L-A, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed. Nat Rev Immunol. 2020;20:389–91.

DOI: 10.1038/s41577-020-0343-0

Wichmann D, Sperhake J-P, Lütgehetmann M, Steurer S, Edler C, Heinemann A, et al. Autopsy findings and venous thromboembolism in patients with COVID-19. Ann Int Med. 2020;173:268–77.

DOI: 10.7326/M20-200

Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol. 2020;6:1108–110.

DOI: 10.1101/2020.02.22.20025320

Luo J, Rizvi H, Preeshagul IR, Egger JV, Hoyos D, Bandlamudi C, et al. COVID-19 in patients with lung cancer. Ann Oncol. 2020;S0923-7534(20)39894-X.

DOI: 10.1016/j.annonc.2020.06.007

Garassino MC, Whisenant JG, Huang L-C, Trama A, Torri V, Agustoni F, et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet. 2020;21:914–22.

DOI: 10.1016/S1470-2045(20)30314-4

Barlesi F, Foulon S, Bayle A, Gachot B, Pommeret F, Willekens C, et al. Abstract CT403: Outcome of cancer patients infected with COVID-19, including toxicity of cancer treatments. Cancer Res. 2020; 80:CT403–CT403.

Luo J, Rizvi H, Egger JV, Preeshagul IR, Wolchok JD, Hellmann MD. Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers. Cancer Discovery. (2020).
DOI: 10.1158/2159-8290.CD-20-0596